More than one study has been demonstrated the efficacy and safety of FP 0.05% cream for proactive therapy of AD. A large multicentre study compared an intermittent dosing regimen of FP 0.05% cream (twice per week) with its drug-free vehicle in reducing the risk of relapse in adults and children (44% and 66% respectively) aged 3 months to 65 years with moderate or severe, but stabilized AD. Both regimens were added to regular daily emollient. The results showed patients receiving intermittent FP cream in the maintenance phase were 7.7 times (paediatric patients even 8.1 times) less likely to have an AD relapse compared with patients under vehicle cream. And the maintenance therapy with FP turned out to be safe and well-tolerated.